Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | F12 | P00748 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16210543 | 0.93 | MAPT (0.50) | MAPTESR2NR1H2MAPK1HPGDS | |
| SCHEMBL1171431 | 0.92 | MAPT (0.43) | MAPTESR2NR1H2MAPK1HPGDS | |
| SCHEMBL1016779 | 0.91 | MAPT (0.48) | MAPTESR2NR1H2MAPK1HPGDS | |
| SCHEMBL25447282 | 0.90 | MAPT (0.47) | MAPTESR2NR1H2MAPK1HPGDS | |
| SCHEMBL23794809 | 0.90 | MAPT (0.47) | MAPTESR2NR1H2MAPK1HPGDS | |
| SCHEMBL20792883 | 0.88 | MAPT (0.46) | MAPTESR2NR1H2MAPK1HPGDS | |
| SCHEMBL30793206 | 0.86 | ESR2 (0.44) | MAPTESR2NR1H2MAPK1HPGDS | |
| SCHEMBL30793116 | 0.85 | MAPT (0.43) | MAPTESR2NR1H2MAPK1HPGDS | |
| SCHEMBL23852158 | 0.83 | MAPT (0.46) | MAPTESR2NR1H2MAPK1HPGDS | |
| SCHEMBL30376605 | 0.82 | HSP90AA1 (0.36) | KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4168407-A1 | BRAF DEGRADERS | C4 Therapeutics, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | MAPT 2440/4885ESR2 2614/4885NR1H2 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.